Creel, García-Cuéllar, Aiza y Enríquez, S.C.

The September-2022 hire of senior associate David Campos -formerly at Baker Mckenzie- marked a notable step in the consolidation of the practice group at Creel, García-Cuéllar, Aiza y Enríquez, S.C.; in addition to ten years private practice experience (and a six-month secondment as in house counsel at Sanofi Pasteur), Campos also has an LLM in Global Health law. He joins a team that is primarily focused on providing regulatory and transactional advice (in the pharma, healthcare, medical device, biotech, and food and beverage industries), on matters such as compliance with sanitary regulations, labelling requirements, and the obtaining of registrations and authorisations, as well as transactional advice and -increasingly- contentious matters. It is also active in relation to the chemical industry, notably as regards the manufacture, import and marketing of toxic and hazardous substances, pesticides, and plant nutrients; and has seen an uptick in specialised administrative litigation related to COFEPRIS’ procedures and verification visits. The practice is co-led by senior regulatory and insurance partner Leonel Pereznieto and counsel Guillermo Govela, a former adviser to the Federal Commissioner at COFEPRIS and legal coordinator at Mexico’s Ministry for Health. Additional associate support is provided by semi-senior Rebeca Díaz (who has a focus on food and non-alcoholic beverage regulation), and Andrés Urbano (whose practice is centred on tobacco and alcoholic beverage regulation); both of them are also key to the firm’s ability to handle the due diligence processes of M&A transactions with a health care/life sciences component. On the contentious front, the team can call on the capabilities of counsel and administrative litigation specialist Héctor Anaya. Recent matters have seen the team particularly active with regard to regulatory reviews, analysis and opinions, while on the healthcare side, it has been engaged in a number of transactions in the private health segment (involving hospitals and clinics), as well as M&A involving laboratories.